|
|
|
Advisory Board
|
Mouse Specifics, Inc. aspires to provide the necessary tools to address the broad spectra of physiological questions presented by mouse models of human disease. Accordingly, we have assembled a team of Advisors, each of whom provides depth and breadth of experience in product development and/or human disease mechanisms and therapies.
William E. Cohn, MD is an Assistant Professor of Medicine, Harvard Medical School and a Cardiothoracic Surgeon at Beth Israel Deaconess Medical Center. He is inventor of the Cohn Cardiac Stabilizer, a revolutionary device that allows surgeons to isolate, stabilize, and suture vessels on a beating heart. His novel biosurgical techniques and devices are significantly improving patient welfare.
Bing Lim, MD, PhD is an Associate Professor of Medicine, Harvard Medical School and an Associate Physician in Hematology/Oncology at Beth Israel Deaconess Medical Center. Dr. Lim's laboratory is focused on identifying novel genes that are important to determining stem cell development and function with particular emphasis on the hematopoietic system. Three areas of on-going research in his laboratory are: 1) function of the ras-related Rho-subfamily of small GTPases; 2) development of embryonic stem cells into different cell lineages; 3) novel lysosomal membrane proteins and proteolysis. Several murine mutant models are being generated, each of which require a variety of methods of assessment, including physiological, biochemical, and molecular.
Youngtack Shim, PhD, JD, is a patent attorney with Pennie & Edmonds LLP, one of the world's largest law firms specializing exclusively in securing, protecting and commercializing intellectual property rights. Dr. Shim earned his M.S. in Chemical Engineering from Korea Adv. Inst. of Science & Technology and his doctorate in Biomedical Engineering from Duke University. He has designed several consumer products and therapeutic devices, and was recently awarded a patent for a drug delivery device to treat impotence. He has published numerous studies in cardiovascular medicine, including several with Thomas G. Hampton through their collaborations at Duke University Medical Center.
Richard L. Verrier, PhD is an Associate Professor of Medicine, Harvard Medical School and a Director of the Institute for Prevention of Cardiovascular Disease at Beth Israel Deaconess Medical Center. His laboratory specializes in computerized analysis of electrocardiographic markers to identify individuals at risk for cardiac arrhythmias and to measure the efficacy of pharmacologic therapy. Dr. Verrier has also spearheaded design and development of novel devices and methods for delivery of angiogenic and myogenic agents to the heart via the pericardial sac.
Ivo Amende, MD is Professor of Cardiology and Professor of Medicine at the Medical University in Hannover, Germany. He is an Interventional Cardiologist with over 30 years of experience in diagnosis and treatment of cardiovascular disease. His interests include global and regional cardiac function in ischemia, hypertrophy, and failure and the effects of novel drugs on cardiac function. Dr. Amende has co-authored over 50 studies in heart research, including several important studies examining mechanisms of cardiovascular regulation in the mouse.
Timothy B. Nash, CFA is a Vice President at Fidelity Investments, a leading investment management, brokerage and benefits outsourcing firm. Having obtained his MBA at The Wharton School in Philadelphia, Mr. Nash currently provides investment reviews and analysis for many of Fidelity's largest investment consultants and corporate clients. He is a member of the Boston Security Analysts Society and a member of the Association for Investment Management and Research.
|
|
